William Blair Has Optimistic Outlook of Lantheus Q1 Earnings

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Stock analysts at William Blair boosted their Q1 2025 EPS estimates for Lantheus in a research report issued on Tuesday, February 4th. William Blair analyst A. Hsieh now forecasts that the medical equipment provider will post earnings per share of $1.78 for the quarter, up from their previous forecast of $1.41. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. William Blair also issued estimates for Lantheus’ Q4 2025 earnings at $1.44 EPS and FY2025 earnings at $5.99 EPS.

A number of other equities research analysts also recently weighed in on LNTH. Truist Financial reaffirmed a “buy” rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. Finally, StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Stock Up 0.5 %

Shares of NASDAQ:LNTH opened at $90.90 on Friday. The company’s fifty day moving average is $92.09 and its two-hundred day moving average is $99.04. The company has a market cap of $6.32 billion, a P/E ratio of 15.12 and a beta of 0.44. Lantheus has a 12-month low of $53.47 and a 12-month high of $126.89.

Institutional Investors Weigh In On Lantheus

Several large investors have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus in the third quarter valued at approximately $25,000. Kestra Investment Management LLC bought a new stake in Lantheus in the 4th quarter worth about $27,000. Signaturefd LLC lifted its holdings in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the period. UMB Bank n.a. boosted its holdings in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 126 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 146 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 2.10% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.